Insider Selling: Avantor, Inc. (NYSE:AVTR) CAO Sells 3,525 Shares of Stock

Avantor, Inc. (NYSE:AVTR) CAO Steven W. Eck sold 3,525 shares of the firm’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $25.06, for a total value of $88,336.50. Following the completion of the transaction, the chief accounting officer now owns 29,544 shares of the company’s stock, valued at $740,372.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Avantor Stock Performance

Shares of AVTR stock traded down $0.09 during mid-day trading on Friday, hitting $25.55. 5,127,880 shares of the stock were exchanged, compared to its average volume of 6,684,110. Avantor, Inc. has a 12-month low of $16.63 and a 12-month high of $28.00. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.05 and a current ratio of 1.59. The stock has a market capitalization of $17.35 billion, a price-to-earnings ratio of 65.74, a P/E/G ratio of 2.64 and a beta of 1.32. The stock’s fifty day simple moving average is $23.77 and its two-hundred day simple moving average is $24.19.

Avantor (NYSE:AVTR) last posted its quarterly earnings data on Friday, July 26th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.02. Avantor had a return on equity of 12.40% and a net margin of 5.28%. The business had revenue of $1.70 billion during the quarter, compared to the consensus estimate of $1.70 billion. On average, analysts forecast that Avantor, Inc. will post 1.01 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Citigroup cut shares of Avantor from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $30.00 to $23.00 in a research note on Wednesday, July 10th. Barclays upped their target price on Avantor from $25.00 to $28.00 and gave the stock an “overweight” rating in a research note on Monday, July 29th. Stifel Nicolaus boosted their price target on Avantor from $27.00 to $28.00 and gave the company a “buy” rating in a report on Monday, July 29th. Wells Fargo & Company assumed coverage on shares of Avantor in a research note on Tuesday, August 27th. They set an “overweight” rating and a $30.00 price objective on the stock. Finally, TD Cowen increased their price target on Avantor from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday, July 29th. Four investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, Avantor presently has a consensus rating of “Moderate Buy” and an average target price of $27.40.

Institutional Trading of Avantor

A number of hedge funds have recently added to or reduced their stakes in AVTR. Versant Capital Management Inc raised its position in shares of Avantor by 2,003.6% in the second quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock valued at $25,000 after buying an additional 1,102 shares during the last quarter. Blue Trust Inc. lifted its holdings in Avantor by 1,830.3% in the 2nd quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock worth $31,000 after buying an additional 1,391 shares in the last quarter. Gladius Capital Management LP acquired a new position in shares of Avantor in the fourth quarter worth about $42,000. Montag A & Associates Inc. acquired a new stake in shares of Avantor during the fourth quarter worth approximately $43,000. Finally, TFO Wealth Partners LLC increased its stake in shares of Avantor by 203,100.0% in the fourth quarter. TFO Wealth Partners LLC now owns 2,032 shares of the company’s stock worth $46,000 after buying an additional 2,031 shares during the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.